The need to protect and treat the 7 billion people on the planet is putting increased pressure on healthcare systems. By 2050, 17 % of the global population is projected to be over 65. This demographic has the highest healthcare spending per capita, as the incidence and prevalence of chronic and acute illnesses rise with age.
Generic medicines are perceived to be an efficacious and cost effective approach for managing health care costs.
The challenges are immense, but with its experience and its expertise, there is an opportunity for Sanophi to take the lead in improving access to quality healthcare.
A generic medicine is a medicine that is developed to be the same as a medicine that has already been authorized (the ‘reference medicine’).
A generic medicine contains the same active substance(s) as the reference medicine, and it is used at the same dose(s) to treat the same disease(s) as the reference medicine. It provides same quality, safety and efficacy as the original brand name product and undergoes strict scrutiny before it is licensed and given market approval by regional or national authorities.
However, the name of the medicine, its appearance (such as colour or shape) and its packaging can be different from those of the reference medicine. Once a generic medicine has been approved for use by patients, its use continues to be monitored closely by the manufacturer and the health authorities. In short, generic medicines comply with the same strict standards of quality, safety and efficacy as original pharmaceutical products.
A generic medicine is marketed in compliance with international patent law. It is identified either by its internationally approved non-proprietary scientific name (INN) or by its own brand name. Generic medicines are widely used in many countries in cost-effective treatment programmes, and are increasingly prescribed by doctors as effective alternatives to higher-priced originator pharmaceuticals.
The key factor in creating a generic medicine is establishing bioequivalence. Bioequivalence means that, when compared scientifically, the generic medicine and the originator product demonstrate essentially the same rate and extent of biological availability of the active substance in the body when administered in the same dose. In simple terms, the generic medicine and the original product must be equally effective.
In an era when increasing demands are being made on healthcare services, generic medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care. The estimated savings each year help provide national healthcare systems with the budget headroom needed to deliver more expensive medical treatments and services that patients often need.
Preventing and Treating
January 4, 2017 - Sanophi Announces Soliqua™ 100/33 Now Available in the U.S.
January 2, 2017 - Sanophi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
December 8, 2016 - Sanophi and Regeneron Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA
November 21, 2016 - Sanophi Receives FDA Approval of Soliqua™ 100/33, for the Treatment of Adults with Type 2 Diabetes